Former VP at Abbott Laboratories Ltd
- Recent trends and developments within the medical device space, focusing on LAAC (left atrial appendage closure) devices
- Comparative analysis of Abbott’s (NYSE: ABT) Amplatzer Amulet against Boston Scientific’s (NYSE: BSX) Watchman FLX
- LAAC’s US TAM opportunity and market growth runway
- Abbott and Boston’s relative sales force acumen and clinician education efforts
- 2023 growth outlook, disruption in LAAC from upstarts and device innovation prospects
Gain access to Premium Content
Submit your details to access up to 5 Forum Transcripts or to request a complimentary one week trial.